InvestorsHub Logo
Followers 134
Posts 3756
Boards Moderated 0
Alias Born 01/28/2006

Re: Minnesinger post# 342044

Thursday, 01/28/2021 10:34:02 PM

Thursday, January 28, 2021 10:34:02 PM

Post# of 403414
The exact quotation:

"Brilacidin’s potent in vitro inhibition of the Washington and Italian strains of SARS-CoV-2 support its potential to inhibit emerging coronavirus mutations (variants), such as those in the United Kingdom, Denmark and South Africa"

https://www.globenewswire.com/news-release/2020/12/21/2148511/0/en/FDA-Grants-IND-Approval-for-Phase-2-Clinical-Trial-of-Innovation-Pharmaceuticals-Brilacidin-for-Treating-COVID-19.html

The PR omits Brilacidin has been found effective against the coronovirus responsible for upper respiratory infections as well as other Coronaviruses to be reported in a separate paper.

"independent preliminary laboratory research suggests Brilacidin, the Company’s flagship defensin mimetic, has the potential to treat other endemic human coronaviruses (H-CoVs), such as those causing common colds, and not just SARS-CoV-2, the novel coronavirus responsible for the ongoing global COVID-19 pandemic. Research shows Brilacidin exerted potent in vitro inhibition of multiple strains of H-CoVs. On completion of testing, the H-CoV findings are expected to be submitted for peer-review publication."

http://www.ipharminc.com/press-release/2020/11/30/innovation-pharmaceuticals-covid-19-clinical-trial-to-support-additional-development-of-brilacidin-as-a-pan-coronavirus-therapeutic

http://www.ipharminc.com/press-release/2020/12/21/fda-grants-ind-approval-for-phase-2-clinical-trial-of-innovation-pharmaceuticals-brilacidin-for-treating-covid-19

No sign of pecuniary intent in my opinion.

GLTA Farrell

Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent IPIX News